Basaglar ® (insulin glargine injection)

100 units/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

BASAGLAR® (insulin glargine injection): Administration and Dosing Instructions

Proper administration and dosing of Basaglar require adherence to specific instructions.

Administration Instructions

Always check insulin labels before administration.1

Instruct patients on proper use and injection technique before initiating Basaglar.1

Visually inspect the Basaglar Pen for particulate matter and discoloration prior to administration. Only use if the solution is clear and colorless with no visible particles.1

Inject between 1 and 80 units of Basaglar per injection.1

Administer Basaglar subcutaneously into the abdominal area, thigh, or deltoid.1

Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy.1

Do not dilute or mix Basaglar with any other insulin or solution as the onset of action or time to peak effect of Basaglar and the mixed insulin may be altered in an unpredictable manner.1

Do not administer Basaglar intravenously or via an insulin pump because this could result in severe hypoglycemia.1

Dosing Instructions

In patients with T1DM, use Basaglar concomitantly with short–acting insulin.1

Inject Basaglar subcutaneously once daily at any time of day but at the same time every day.1

Individualize and titrate the dosage of Basaglar based on the individual’s

  • metabolic needs

  • BG monitoring results

  • glycemic control goal

  • type of DM, and

  • prior insulin use.1

Perform dosage adjustments of Basaglar under medical supervision and with appropriate glucose monitoring. Dosage adjustments may be needed with

  • changes in physical activity

  • changes in meal patterns, such as with macronutrient content or timing of food intake

  • episodes of acute illness, or

  • changes in renal or hepatic function.1

Enclosed Prescribing Information

BASAGLAR® (insulin glargine injection), for subcutaneous use, Lilly


1. Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018.


Basaglar = Basaglar® (insulin glargine injection) 100 units/mL

BG = blood glucose

DM = diabetes mellitus

Pen = KwikPen®

T1DM = type 1 diabetes mellitus

Date of Last Review: July 22, 2019

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical